glp-1 medications approved for type 2 diabetes 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with GLP-1 Drugs: 2025 Pulse Survey

Sarah Armstrong, pediatrician and medical weight management specialist with Duke Health, called the coverage game changing for all North Carolinians. Armstrong is also a member of the executive committee of the American Academy of Pediatrics Section on Obesity

The Influence and Mechanism of GLP-1 RAs in Modulating Hypertension Hypertension, a chronic cardiovascular disease, affects a large number of individuals, with its prevalence increasing, making it a major cause of mortality and disability [72]

And thats what we care about and we need to take care of our patients

00:09:24 Steve Small: Yep, thats a really good call out here and use our Treatment and Prevention of Hair Loss chart for a list of possible options to think about

Tohme 3 Shaun Shadaker 3 Irina Tskhomelidze 3 Ekaterine Adamia 4 Tamar Gabunia 5 , 1 Infectious Diseases, AIDS and Cl

Struan Coleman, a Board-Certified Orthopedic Surgeon and Microbiologist, and Danielle Schupp, a Registered Dietitian and Sports Nutritionist